Variability in UDP-glucuronosyltransferase genes and morphine metabolism: Observations from a cross-sectional multicenter study in advanced cancer patients with pain

Pharmacogenetics and Genomics

Volumn 23, Issue 3, 2013, Pages 117-126

  Fladvad, Torill ^a,b   Klepstad, Pål ^a,d   Langaas, Mette ^c   Dale, Ola ^a,d   Kaasa, Stein ^a,d   Caraceni, Augusto ^e   Skorpen, Frank ^a,b  

^a European Palliative Care Research Center (PRC)   (Norway)

^b Faculty of Medicine   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

morphine; morphine 3 glucuronide; morphine 6 glucuronide; polymorphism; UDP glucuronosyltransferase

Indexed keywords

GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; PARACETAMOL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER PAIN; CANCER PATIENT; CROSS-SECTIONAL STUDY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY FUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 84873412753     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835ce485     Document Type: Article

References (55)

1. Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-1145.
2. Hanks G, Cherny N, Fallon M. Opioid analgesic therapy. In: Doyle D, et al., editor. Oxford textbook of palliative medicine. Oxford: Oxford University Press; 2005. pp. 334-335.
3. Klepstad P, Dale O, Kaasa S, Zahlsen K, Aamo T, Fayers P, et al. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 cancer patients. Acta Anaesthesiol Scand 2003; 47:725-731.
4. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000; 55:713-719.
5. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 1997; 14:157-167.
6. Faura CC, Collins SL, Moore RA, McQuay HJ. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74:43-53.
7. Hanna MH, Elliott KM, Fung M. Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. Anesthesiology 2005; 102:815-821.
8. Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg 2007; 105:70-78.
9. Romberg R, van Dorp E, Hollander J, Kruit M, Binning A, Smith T, et al. A randomized, double-blind, placebo-controlled pilot study of IV morphine-6-glucuronide for postoperative pain relief after knee replacement surgery. Clin J Pain 2007; 23:197-203.
10. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PEM, Dahan A. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 2004; 100:120-133.
11. Smith TW, Binning AR, Dahan A. Efficacy and safety of morphine-6-glucuronide (M6G) for postoperative pain relief: a randomized, double-blind study. Eur J Pain 2009; 13:293-299.
12. Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 32:130-138.
13. Andersen G, Christrup L, Sjögren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage 2003; 25:74-91.
14. Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 2010; 165:569-583.
15. Sear JW, Hand CW, Moore RA. Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. J Clin Anesth 1989; 1:164-169.
16. Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. Age Ageing 1989; 18:258-262.
17. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25:1-4.
18. Holthe M, Rakvag TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003; 3:17-26.
19. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1&z.ast;28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58:353-356.
20. Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73: 566-574.
21. Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004; 75:223-233.
22. Fisher MB, VandenBranden M, Findlay K, Burchell B, Thummel KE, Hall SD, et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 2000; 10: 727-739.
23. Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 2008; 36:688-694.
24. Ritter JK. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 2007; 3:93-107.
25. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61:47-54.
26. Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P, et al. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 2003; 17: 679-687.
27. Mercadante S. The role of morphine glucuronides in cancer pain. Palliat Med 1999; 13:95-104.
28. Darbari DS, van Schaik RHN, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant-840G> A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008; 83:200-202.
29. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 2003; 31: 1086-1089.
30. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP- glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171-1175.
31. Maruo Y, D'Addario C, Mori A, Iwai M, Takahashi H, Sato H, et al. Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum Genet 2004; 115: 525-526.
32. Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K, et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15:35-41.
33. Li X, Bratton S, Radominska-Pandya A. Human UGT1A8 and UGT1A10 mRNA are expressed in primary human hepatocytes. Drug Metab Pharmacokinet 2007; 22:152-161.
34. World Health Organization. WHO's pain ladder. World Health Organization. Available at: http://www.who.int/cancer/palliative/painladder/en/[Accessed December 2011].
35. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-656.
36. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17:197-210.
37. Folstein MF, Folstein SE, McHugh PR.'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
38. Tyrefors N, Hyllbrant B, Ekman L, Johansson M, Langström B. Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. J Chromatogr A 1996; 729: 279-285.
39. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1991; 16: 249-255.
40. Dadgar D, Burnett PE, Choc MG, Gallicano K, Hooper JW. Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal 1995; 13:89-97.
41. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 2007; 81:559-575.
43. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
44. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
45. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292: 492-497.
46. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75:501-515.
47. Hendrix-Treacy S, Wallace SM, Hindmarsh KW, Wyant GM, Danilkewich A. The effect of acetaminophen administration on its disposition and body stores of sulphate. Eur J Clin Pharmacol 1986; 30:273-278.
48. Hindmarsh KW, Mayers DJ, Wallace SM, Danilkewich A, Ernst A. Increased serum sulfate concentrations in man due to environmental factors: effects on acetaminophen metabolism. Vet Hum Toxicol 1991; 33:441-445.
49. Gelotte CK, Auiler JF, Lynch JM, Temple AR, Slattery JT. Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin Pharmacol Ther 2007; 81:840-848.
50. Milne R, Nation R, Somogyi A, Bochner F, Griggs W. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 1992; 34:53-59.
51. Andreassen T, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 2011; 67:493-506.
52. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48:236-244.
53. Patwardhan R, Johnson R, Hoyumpa AJ, Sheehan J, Desmond P, Wilkinson G, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981; 81:1006-1011.
54. Stuart-Harris R, Joel S, McDonald P, Currow D, Slevin M. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 2000; 49:207-214.
55. Galvan A, Fladvad T, Skorpen F, Gao X, Klepstad P, Kaasa S, et al. Genetic clustering of European cancer patients indicates that opioid-mediated pain relief is independent of ancestry. Pharmacogenomics J 2011; 12:412-416.